| Document |
Document Title |
|
WO/2024/069191A1 |
The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volum...
|
|
WO/2024/069006A1 |
Composition for use in performing a soft tissue surgery procedure in a subject in need thereof, wherein a drug delivery device is placed at a surgical site for controlled and/or sustained release of bupivacaine hydrochloride, said drug d...
|
|
WO/2024/062423A1 |
The invention provides an oromucosal film composition comprising: a therapeutically effective amount of one or more active pharmaceutical ingredients selected from the group consisting of fluticasone, liraglutide, glucagone, midazolam, d...
|
|
WO/2024/053625A1 |
The purpose of the present invention is to provide a means for shortening the time of development of the action of a local anesthetic agent, an antihistamine drug or the like against skin and oral mucosa. Provided are: a minute project...
|
|
WO/2024/037564A1 |
The present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof, or a deuterated compound t...
|
|
WO/2024/026337A1 |
This invention relates to crystalline solvated forms of Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solvated solid forms of Compound (1), and methods of using the crystall...
|
|
WO/2024/024520A1 |
Provided is a composition for an external preparation, the composition comprising the below-mentioned components (A) to (D), in which the component (B) comprises at least two components selected from the group consisting of (B1) a cellul...
|
|
WO/2024/015597A1 |
This disclosure relates to compositions for treating skin conditions and improving skin health. In particular, the disclosure relates to compositions formulated as an absorbent article to be topically applied to skin, the absorbent artic...
|
|
WO/2024/012361A1 |
Provided are an alphaxalone fat emulsion injection and a method for preparing same. The alphaxalone fat emulsion injection comprises alphaxalone and a pharmaceutically acceptable salt thereof, an oil phase, an emulsifier, a co-emulsifier...
|
|
WO/2024/012397A1 |
The present invention relates to a compound having a structure represented by formula I, formula II, formula III, formula IV, formula V or formula VI, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical compos...
|
|
WO/2024/009542A1 |
The present invention addresses the problem of providing a new injection liquid that is for dental local anesthesia and that is capable of reducing a patient's indefinite complaint that may be caused after a treatment, particularly an un...
|
|
WO/2023/242696A1 |
Provided is at least one terpene for use in modulation of a physiological function via modulation of activation of a Transient Receptor Potential (TRP) channel receptor, wherein the TRP is a member of subfamily A (TRPA) and the terpene i...
|
|
WO/2023/236981A1 |
Disclosed are a polyaminoacid vector type amide local anesthetic sustained-release drug, a method for preparing the same and use thereof, which belong to the field of drug sustained release. The drug comprises an active component, wherei...
|
|
WO/2023/230175A1 |
This disclosure relates to a composition comprising an anti-inflammatory agent and an analgesic agent for treating anal gland disease. In particular, the disclosure relates to a composition formulated as a spray or wipe.
|
|
WO/2023/221952A1 |
Provided in the present application are a cyclic quaternary ammonium salt compound, and a preparation method therefor and the use thereof. Further provided are the cyclic quaternary ammonium salt compound as represented by general formul...
|
|
WO/2023/215277A1 |
The present disclosure relates to trimeprazine for use in methods of treating trigeminal neuralgia and pain related thereto, by administering to a patient in need thereof a therapeutically effective amount of trimeprazine. The methods ma...
|
|
WO/2023/214751A1 |
The present invention relates to a soluble microneedle for local anesthesia and a local anesthesia patch comprising same, the soluble microneedle comprising an amide-based local anesthetic, hyaluronic acid, and polyvinylpyrrolidone in a ...
|
|
WO/2023/208059A1 |
The present invention provides a thermosensitive modified chitin sponge drug-loaded implanted sustained-release system, a preparation method therefor, and use thereof. The system comprises the following components: a spongy matrix, the m...
|
|
WO/2023/205865A1 |
This invention refers to a herbal formulation to treat sexual dysfunctions. More specifically, the present invention relates to a herbal formulation containing standardized extract of Spilanthes acmella, useful as an adjuvant in the prev...
|
|
WO/2023/196169A1 |
The disclosure relates to methods for pain management in the perioperative context, particularly through the use of one or more biomarkers such as the DNA methylation status in genes of the PARK16 locus.
|
|
WO/2023/183153A1 |
A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in compar...
|
|
WO/2023/154293A1 |
An anesthetic formulation that includes bupivacaine, epinephrine, Ketorolac, Dexmedetomidine, and Dexamethasone demonstrates improved pain reduction and diminished opioid use in an ERAS protocol. Additional aspects include implementation...
|
|
WO/2023/130050A1 |
Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and/or management of pain and related conditions, including post-operative pain, pain incident to an incision or wound, chronic p...
|
|
WO/2023/120517A1 |
[Problem] To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened. [Solution] A poultice comprising a support layer, a paste layer, and a release liner layer, wherein the paste layer comprises a ...
|
|
WO/2023/104960A1 |
The present disclosure relates to Meteorin and its use in prevention and/or treatment of nociceptive pain. Acute and chronic nociceptive pain caused by e.g. injuries to the body or inflammation may be treated by administration of Meteori...
|
|
WO/2023/100836A1 |
The present invention addresses the problem of providing a pharmaceutical composition that is for local use and that is appropriate for the alleviation of pain in the oral cavity and/or the pharynx. This pharmaceutical composition for ...
|
|
WO/2023/100740A1 |
This adhesive patch is characterized by comprising a support and a pressure-sensitive adhesive layer provided on the support, and is characterized in that the pressure-sensitive adhesive layer contains a local anesthetic, a thermoplastic...
|
|
WO/2023/094100A1 |
The invention provides a gastro-retentive oral dosage unit having a weight of 150-1,000 mg, said dosage unit comprising 70-100 wt.% of a core unit and 0-30 wt.% of a coating, the core unit comprising: (a) 15-50 wt.% local anaesthetic; (b...
|
|
WO/2023/083191A1 |
Provided are a benzodiazepine compound, and a preparation method therefor and a medical use thereof, relating to the field of chemical medicines. The benzodiazepine compound is a compound represented by formula I, or a salt thereof, or a...
|
|
WO/2023/081185A1 |
Disclosed in certain embodiments is a method of treating respirator^/ depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as discl...
|
|
WO/2023/080886A1 |
Compositions containing an anesthetic and an extracellular matrix component or fragment thereof and methods for treating pain by topically administering such compositions are described herein.
|
|
WO/2023/035173A1 |
An anesthetic composition for topical application comprises:(a) therapeutically effective amount of at least one pharmaceutically active agent;(b) at least one pharmaceutically acceptable solvent vehicle;(c) at least one clay;wherein the...
|
|
WO/2023/031862A1 |
Provided is a method for treating a condition related to cannabinoid type 1 (CB1) receptor activation by administering a composition comprising at least one terpene, optionally together with tetrahydrocannabinol (THC). Further provided i...
|
|
WO/2023/016565A1 |
Disclosed are a microsphere suspension, a microparticle formulation, and a preparation method therefor. The microparticle formulation comprises an active pharmaceutical ingredient and a PLGA. The molar ratio of lactide LA to glycolide GA...
|
|
WO/2023/274258A1 |
Provided are a heteroatom-substituted aromatic compound, and a preparation method therefor and the use thereof, which belong to the field of medicinal chemistry. The compound is a compound as represented by formula I, or a salt, a stereo...
|
|
WO/2022/267798A1 |
A conjugate formed by covalently bonding a polypeptide represented by structural formula I to a fentanyl derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing these compounds as active ingredi...
|
|
WO/2022/263476A1 |
The present invention relates to combinations of local anesthetics for improved pain relief in patients.
|
|
WO/2022/256878A1 |
This invention relates to a topical anaesthetic composition having improved adrenaline stability, its method of manufacture, and its use as a topical anaesthetic, particularly in medical applications such as animal husbandry procedures.
|
|
WO/2022/256708A1 |
Provided is a solid dispersion of (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dime
thyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (Compound 1), defined as described herein, or a pharmaceutica...
|
|
WO/2022/247914A1 |
Provided are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. The compound represented by general formula (I), or an isomer or pharmaceutically acceptable salt thereof, and a composition thereof can b...
|
|
WO/2022/041171A9 |
The present application relates to a compound having the effects of being an antidepressant, narcotizing, alleviating pain, improving cognitive functions, protecting lungs, preventing or treating amyotrophic lateral sclerosis, or prevent...
|
|
WO/2022/241527A1 |
The present invention describes the obtaining of chitosan membranes associated with the extract from the medicinal plant Acmella oleracea by incorporation of the raw extract (E) and the butanolic fraction (FB) thereof into the biomateria...
|
|
WO/2022/237849A1 |
The present invention relates to a NMDA receptor antagonist and use thereof. The NMDA receptor antagonist of the present invention is a compound of formula I below, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a ...
|
|
WO/2022/236369A1 |
A surgical tunneling tool and a method of using the surgical tunneling tool are disclosed. In one embodiment, the surgical tunneling tool includes a flexible shaft including a lumen through which an anesthetic may be delivered subcutaneo...
|
|
WO/2022/238965A1 |
Described is an anhydrous transdermal formulation comprising one or more active agents, at least 15% by weight terpene hydrocarbon, a veterinary acceptable aprotic solvent, and a veterinary acceptable C2 to C6 volatile solvent having a f...
|
|
WO/2022/241257A1 |
Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinu...
|
|
WO/2022/233989A1 |
The present disclosure relates to Meteorin and its use in prevention and/or treatment of chemotherapy-induced neuropathic pain. Neuropathic pain arising as a result of treatment with a chemotherapeutic may be treated by administration of...
|
|
WO/2022/229446A1 |
The present invention relates to the field of anesthetics. Especially, the present invention refers to an injectable anesthetic solution having a reduced bitterness comprising: - an anesthetic agent; - optionally, a vasoconstrictor; - a ...
|
|
WO/2022/215693A1 |
The present invention provides a microneedle preparation which can be applied to an oral cavity easily, exerts an anesthetic effect suitable for a site of application, and has excellent stability. Provided is a quick-acting local anest...
|
|
WO/2022/212892A1 |
The present disclosure provides, amongst other things, pharmaceutical compositions, kits and methods for treatment of anal fissures using a medicated topical wipe comprising Nifedipine and Lidocaine.
|
